Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is $7.91 and the consensus Revenue Estimate ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Pfizer (NYSE: PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue ...

As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...